Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023)

Historic EBIT Margin for Benitec Biopharma (BNTC) over the last 5 years, with Q2 2023 value amounting to 65000.0%.

  • Benitec Biopharma's EBIT Margin changed N/A to 65000.0% in Q2 2023 from the same period last year, while for Mar 2024 it was 307028.57%, marking a year-over-year decrease of 2786918100.0%. This contributed to the annual value of 25441.33% for FY2023, which is 9838000.0% down from last year.
  • According to the latest figures from Q2 2023, Benitec Biopharma's EBIT Margin is 65000.0%.
  • Over the past 5 years, Benitec Biopharma's EBIT Margin peaked at 8248.57% during Q2 2020, and registered a low of 379300.0% during Q1 2021.
  • Moreover, its 5-year median value for EBIT Margin was 8038.89% (2023), whereas its average is 80620.4%.
  • As far as peak fluctuations go, Benitec Biopharma's EBIT Margin plummeted by 2000000000bps in 2021, and later soared by 2000000000bps in 2022.
  • Over the past 5 years, Benitec Biopharma's EBIT Margin (Quarter) stood at 2741.56% in 2019, then tumbled by -11787bps to 325900.0% in 2020, then skyrocketed by 94bps to 19340.0% in 2021, then tumbled by -107bps to 40071.43% in 2022, then tumbled by -62bps to 65000.0% in 2023.
  • Its last three reported values are 65000.0% in Q2 2023, 8038.89% for Q1 2023, and 40071.43% during Q4 2022.